sNN0031

sNN0031 is a novel drug candidate developed for the treatment of Parkinson’s disease. It is a recombinant human platelet-derived growth factor-BB (rhPDGF-BB), formulated for intracerebroventricular (ICV) delivery via an implantable pump and brain catheter. The drug acts on neural stem and progenitor cells in the brain, aiming to restore motor function and improve neurochemical deficits by stimulating proliferation of subventricular and striatal cells. In animal models of Parkinson’s disease, sNN0031 has shown long-lasting improvements in symptoms and dopamine system integrity. Clinical studies have demonstrated that ICV administration of sNN0031 is well tolerated with preliminary beneficial effects on biochemical markers related to dopaminergic neurons. Its mechanism involves acting as an agonist at both the dopamine transporter (DAT) and platelet-derived growth factor receptor (PDGFR), potentially halting or reversing disease progression rather than just alleviating symptoms[1][2][3][7].

Other names

rhPDGF-BBrecombinant human platelet-derived growth factor-BBPDGF-BB